This analysis demonstrated that there is a significantly shorter overall survival for lung cancer patients with IL-6 mRNA levels above the median value (HR = 1.32, longrank p = 1.7e-05, n = 1926) (Fig. 6a). This evidence concerns the gene IL6 and lung carcinoma.